Cargando…
Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers
Despite its use for decades, pharmacokinetic (PK) and safety studies on colistin are limited. We conducted a phase l, open-label trial to evaluate the safety and PK of multiple doses of intravenous (IV) and aerosolized colistimethate sodium (CMS) administered separately and in combination. In total,...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029538/ https://www.ncbi.nlm.nih.gov/pubmed/35453240 http://dx.doi.org/10.3390/antibiotics11040490 |
_version_ | 1784691903515590656 |
---|---|
author | Yendewa, George A. Griffiss, John McLeod Gray, Wesley A. Healen, Amanda Proskin, Howard M. Fulton, Scott A. O’Riordan, Mary Ann Hoppel, Charles Blumer, Jeffrey L. Salata, Robert A. |
author_facet | Yendewa, George A. Griffiss, John McLeod Gray, Wesley A. Healen, Amanda Proskin, Howard M. Fulton, Scott A. O’Riordan, Mary Ann Hoppel, Charles Blumer, Jeffrey L. Salata, Robert A. |
author_sort | Yendewa, George A. |
collection | PubMed |
description | Despite its use for decades, pharmacokinetic (PK) and safety studies on colistin are limited. We conducted a phase l, open-label trial to evaluate the safety and PK of multiple doses of intravenous (IV) and aerosolized colistimethate sodium (CMS) administered separately and in combination. In total, 31 healthy adults were enrolled into three cohorts of 9, 10, and 12 participants, respectively. Each cohort received increasing doses of CMS over three dosing periods as follows: Period 1 (IV only), 2.5 mg/kg every 12 h (q12h) to 3.3 mg/kg every 8 h (q8h); Period 2 (aerosolized only), 75 mg 2–4 doses, and Period 3 (combined IV aerosolized), in which was Periods 1 and 2 combined. Safety assessments, serum and lung concentrations of colistin analytes (colistin A, colistin B, CMS A, and CMS B), and kidney biomarkers were measured at specified time points. Increasing the CMS dose from 2.5 mg/kg q12h to q8h resulted in a 33% increase in serum colistin A concentrations from 3.9 μg/mL to 5.3 μg/mL—well above the accepted target of 2 μg/mL for 6 h after dosing, without evidence of nephrotoxicity. However, there was an increase in neurotoxicity, primarily perioral and lingual paresthesias, and self-limited ataxia. IV administration did not increase the lung concentrations of colistin. |
format | Online Article Text |
id | pubmed-9029538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90295382022-04-23 Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers Yendewa, George A. Griffiss, John McLeod Gray, Wesley A. Healen, Amanda Proskin, Howard M. Fulton, Scott A. O’Riordan, Mary Ann Hoppel, Charles Blumer, Jeffrey L. Salata, Robert A. Antibiotics (Basel) Article Despite its use for decades, pharmacokinetic (PK) and safety studies on colistin are limited. We conducted a phase l, open-label trial to evaluate the safety and PK of multiple doses of intravenous (IV) and aerosolized colistimethate sodium (CMS) administered separately and in combination. In total, 31 healthy adults were enrolled into three cohorts of 9, 10, and 12 participants, respectively. Each cohort received increasing doses of CMS over three dosing periods as follows: Period 1 (IV only), 2.5 mg/kg every 12 h (q12h) to 3.3 mg/kg every 8 h (q8h); Period 2 (aerosolized only), 75 mg 2–4 doses, and Period 3 (combined IV aerosolized), in which was Periods 1 and 2 combined. Safety assessments, serum and lung concentrations of colistin analytes (colistin A, colistin B, CMS A, and CMS B), and kidney biomarkers were measured at specified time points. Increasing the CMS dose from 2.5 mg/kg q12h to q8h resulted in a 33% increase in serum colistin A concentrations from 3.9 μg/mL to 5.3 μg/mL—well above the accepted target of 2 μg/mL for 6 h after dosing, without evidence of nephrotoxicity. However, there was an increase in neurotoxicity, primarily perioral and lingual paresthesias, and self-limited ataxia. IV administration did not increase the lung concentrations of colistin. MDPI 2022-04-06 /pmc/articles/PMC9029538/ /pubmed/35453240 http://dx.doi.org/10.3390/antibiotics11040490 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yendewa, George A. Griffiss, John McLeod Gray, Wesley A. Healen, Amanda Proskin, Howard M. Fulton, Scott A. O’Riordan, Mary Ann Hoppel, Charles Blumer, Jeffrey L. Salata, Robert A. Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers |
title | Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers |
title_full | Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers |
title_fullStr | Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers |
title_full_unstemmed | Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers |
title_short | Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers |
title_sort | dosing colistimethate every 8 h results in higher plasma concentrations of active colistin than every 12-hourly dosing without increase in nephrotoxicity: a phase 1 pharmacokinetics trial in healthy adult volunteers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029538/ https://www.ncbi.nlm.nih.gov/pubmed/35453240 http://dx.doi.org/10.3390/antibiotics11040490 |
work_keys_str_mv | AT yendewageorgea dosingcolistimethateevery8hresultsinhigherplasmaconcentrationsofactivecolistinthanevery12hourlydosingwithoutincreaseinnephrotoxicityaphase1pharmacokineticstrialinhealthyadultvolunteers AT griffissjohnmcleod dosingcolistimethateevery8hresultsinhigherplasmaconcentrationsofactivecolistinthanevery12hourlydosingwithoutincreaseinnephrotoxicityaphase1pharmacokineticstrialinhealthyadultvolunteers AT graywesleya dosingcolistimethateevery8hresultsinhigherplasmaconcentrationsofactivecolistinthanevery12hourlydosingwithoutincreaseinnephrotoxicityaphase1pharmacokineticstrialinhealthyadultvolunteers AT healenamanda dosingcolistimethateevery8hresultsinhigherplasmaconcentrationsofactivecolistinthanevery12hourlydosingwithoutincreaseinnephrotoxicityaphase1pharmacokineticstrialinhealthyadultvolunteers AT proskinhowardm dosingcolistimethateevery8hresultsinhigherplasmaconcentrationsofactivecolistinthanevery12hourlydosingwithoutincreaseinnephrotoxicityaphase1pharmacokineticstrialinhealthyadultvolunteers AT fultonscotta dosingcolistimethateevery8hresultsinhigherplasmaconcentrationsofactivecolistinthanevery12hourlydosingwithoutincreaseinnephrotoxicityaphase1pharmacokineticstrialinhealthyadultvolunteers AT oriordanmaryann dosingcolistimethateevery8hresultsinhigherplasmaconcentrationsofactivecolistinthanevery12hourlydosingwithoutincreaseinnephrotoxicityaphase1pharmacokineticstrialinhealthyadultvolunteers AT hoppelcharles dosingcolistimethateevery8hresultsinhigherplasmaconcentrationsofactivecolistinthanevery12hourlydosingwithoutincreaseinnephrotoxicityaphase1pharmacokineticstrialinhealthyadultvolunteers AT blumerjeffreyl dosingcolistimethateevery8hresultsinhigherplasmaconcentrationsofactivecolistinthanevery12hourlydosingwithoutincreaseinnephrotoxicityaphase1pharmacokineticstrialinhealthyadultvolunteers AT salataroberta dosingcolistimethateevery8hresultsinhigherplasmaconcentrationsofactivecolistinthanevery12hourlydosingwithoutincreaseinnephrotoxicityaphase1pharmacokineticstrialinhealthyadultvolunteers |